Thursday, April 30, 2026
12:00 pm – 1:30 pm CT / 1:00 pm – 2:30 pm ET
Register
Cost: FREE for SIDP, ACCP ID PRN and CLSI Members! $15 for non-member attendees
- SIDP members: No code needed. Login using your SIDP account to enroll at no cost.
- ACCP ID PRN members: create an SIDP login then enter the code provided by your membership group in the Enrollment Key box to participate in this activity at no cost.
- CLSI members: coming soon!
This annual continuing education webinar delivers the latest updates to CLSI M100 Standards for Antimicrobial Susceptibility Testing and explores practical approaches for integrating these changes into clinical workflows. Faculty will highlight the critical partnership between pharmacists and laboratory professionals to support effective implementation and optimize patient care outcomes. Interactive audience polling will be incorporated throughout the session, followed by a live Q&A discussion.
Target Audience:
This activity was planned to meet the educational needs of Pharmacists and Laboratory Professionals.
Learning Objectives:
- Describe updates in the 2026 CLSI M100 performance standards related to breakpoints and susceptibility testing for aztreonam-avibactam for Enterobacterales, trimethoprim-sulfamethoxazole susceptibility testing for beta-hemolytic Streptococcus species, and antibiogram use for empiric treatment of infections due to anaerobic organisms
- Discuss strategies to integrate new breakpoints, susceptibility testing considerations, and anaerobic antibiogram data into laboratory and patient care workflows to support clinical decision-making
- Identify opportunities for laboratory and clinical teams to collaborate on implementation of CLSI M100 2026 updates to enhance infectious diseases practices and improve patient care
Faculty:
Kevin Alby, PhD, D(ABMM)
Director of Microbiology
Brown University Health
Providence, RI
Kate DeSear, PharmD, BCIDP, FIDSA
Clinical Associate Professor
Department of Pharmacy Practice and Education
University of Florida, College of Pharmacy
Gainesville, FL
Accreditation:
Pharmacist
This activity is jointly provided by the Society of Infectious Diseases Pharmacists (SIDP) and the American College of Clinical Pharmacy Infectious Diseases Practice and Research Network (ACCP ID PRN). SIDP is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
UAN: 0672-0000-26-006-L01-P
CPE credit: 1.5 contact hour (0.15 CEU)
Type of activity: Knowledge
Release Date: April 30, 2026
Expiration Date: April 30, 2029
Activity Fee: SIDP, CLSI and ACCP ID PRN Member: Free / Non-Member: $15
To receive CE credit, participants must view the content, then complete a post-test self-assessment with a passing score of 70% or greater, and complete an activity evaluation online. Proof of completion will be submitted to NABP CPE Monitor.
Per ACPE requirements, CPE credit must be claimed within 60 days of being earned. Participants are responsible for verifying credits were transferred successfully to your NABP eProfile account before the ACPE 60-day deadline. After the 60 day deadline, SIDP will no longer be able to report your credit(s) for this activity.
PACE
Clinical and Laboratory Standards Institute is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E.(R) Program.
Funding:
This activity is self-funded by SIDP, CLSI, and members of ACCP ID PRN.
Disclosures:
In accordance with the Standards for Integrity and Independence in Accredited Continuing Education, SIDP asks all individuals involved in the development and presentation of CE activities to disclose all financial relationships with ineligible companies. All relevant financial relationships have been mitigated prior to the CE activity. The following financial relationships have been disclosed:
- Dr. DeSear has served as a consultant/advisor/speaker for Abbvie, Shionogi, Cormedix, and Biomerieux.
- Dr. Alby's disclosures will be available prior to the webinar.
- SIDP planners, staff and other individuals who are in a position to control the content of this CE activity have no relevant financial relationships with an ineligible company to disclose.
- Presentation title and objectives were written by the planning committee and enhanced by AI. All enhancements were reviewed by a human.
Disclaimer:
Faculty members are asked to disclose when any unlabeled/investigational use of pharmaceuticals and devices is being discussed. This activity is intended for educational purposes and should not be used as a substitute for care or advice from a professional. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of SIDP.
The planners and faculty of this continuing education activity have made all reasonable efforts to ensure the accuracy of the information presented in accordance with the latest available scientific knowledge at the time of publication. Healthcare professionals should verify all information and data with recommendations of other authorities before treating patients or employing any therapies described in this continuing education activity.
.gif){kind=logo}